Swedish stocks: Seen opening higher, Sobi buys infant drug rights for $1.5 bln

Ambea publ AB

13/11/2018 07:50

** Swedish shares seen opening higher on Tuesday in line with European
markets 
    **  Asian shares pared losses on Tuesday as hopes for a de-escalation in the
Sino-U.S. tariff war rose on a report that China's top trade negotiator was
preparing to visit the United States ahead of a meeting between the two
countries' leaders  urn:newsml:reuters.com:*:nL4N1XO2NQ
    ** AstraZeneca sells infant drug rights to Sobi  SOBIV.ST  for $1.5 bln
upfront  urn:newsml:reuters.com:*:nL8N1XO1OY
    ** Activist fund Cevian Capital analyzes Nordea  NDASE.ST   NDAFI.HE  ahead
of a potential investment in the bank, daily Dagens Industri reports referring
to sources  urn:newsml:reuters.com:*:nL8N1XO1PS
    ** Paradox Interactive  PDXI.ST  Q3 operating profit up at SEK 68 mln
 urn:newsml:reuters.com:*:nFWN1XO049
    ** Ambea  AMBEA.ST  Q3 EBIT rises to SEK 184 mln  urn:newsml:reuters.com:*:nFWN1XO01U
    ** Alfa Laval  ALFA.ST  wins pumping system orders worth 175 mln SEK
 urn:newsml:reuters.com:*:nFWN1XN1A3
    
        
 IG pre-market trading Stockholm OMXS30                     +0.4 pct
 Stoxx Europe 50 future                   STXEc1            +0.2 pct 
 MSCI index Asia Pacific ex Japan         .MIAPJ0000PUS     -0.3 pct 
 S&P 500 close previous trading day       .SPX              -2.0 pct 
 
    
    For European stock market report:  .EU 
    For global market roundup.  MKTS/GLOB 
    
    

 (RM:olof.swahnberg.thomsonreuters.com@reuters.net)